ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 27 of 146 for:    "Retinitis pigmentosa"

Natural History Study of Patients With X-linked Retinal Dystrophy Associated With Mutations in Retinitis Pigmentosa GTPase Regulator (RPGR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03349242
Recruitment Status : Recruiting
First Posted : November 21, 2017
Last Update Posted : January 31, 2018
Sponsor:
Information provided by (Responsible Party):
MeiraGTx UK II Ltd

Brief Summary:
The rod-cone dystrophies (often referred to as retinitis pigmentosa (RP)) are a clinically and genetically heterogeneous group of disorders in which there is progressive loss of rod and later cone photoreceptor function leading to severe visual impairment. RP usually occurs as an isolated retinal disorder, but it may also be seen in association with systemic abnormalities.

Condition or disease
Retinitis Pigmentosa

Detailed Description:
X-linked Retinitis Pigmentosa (XLRP) is a severe form of RP with early onset of nyctalopia and progression to legal blindness by the 3rd to 4th decade. Most affected males show symptomatic night blindness before the age of 10 years, are often myopic and show fundus abnormalities and ERG changes in early childhood. Examination of close female relatives is helpful in the absence of a family history, as the recognition of the XL carrier state will confirm the diagnosis.

Study Type : Observational
Estimated Enrollment : 55 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: Natural History Study of Patients With X-linked Retinal Dystrophy Associated With Mutations in Retinitis Pigmentosa GTPase Regulator (RPGR)
Actual Study Start Date : December 19, 2017
Estimated Primary Completion Date : December 30, 2022
Estimated Study Completion Date : December 30, 2022





Primary Outcome Measures :
  1. Analysis of retinal structure and function to assess disease progression [ Time Frame: 6 years ]
    Retinal structure will be measured using Adaptive optics and SD-OCT and Fundal autofluorescence.


Secondary Outcome Measures :
  1. Retinal Sensitivity [ Time Frame: 6 years ]
    To be assessed by Microperimetry (KEC site only)

  2. Retinal Structural detailed phenotyping [ Time Frame: 6 years ]
    Retinal Structure measured by Adaptive Optics (KEC site only)

  3. Fundus Autofluorescence [ Time Frame: 6 years ]
    Presence or Absence

  4. Visual Fields testing [ Time Frame: 6 years ]
    Assessment of Visual Fields with analysis of hill vision by perimetry



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   5 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with RPGR-associated retinal dystrophy
Criteria

Inclusion Criteria:

  • Males aged 5 years or older
  • Have RPGR-associated retinal dystrophy
  • Are able to give informed consent or assent, with the guidance of their parent/guardian where appropriate
  • Are able to undertake age-appropriate clinical assessments as specified in the protocol

Exclusion Criteria:

  • Are unable or unwilling to undertake consent or clinical testing

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03349242


Contacts
Contact: Anna Morka, MSc +44 (0) 20 3866 4320 ocularinfo@meiragtx.com

Locations
United States, Massachusetts
Massachusetts Eye and Ear Infirmary Recruiting
Boston, Massachusetts, United States, 02114
Contact: Alicia Kaneb    617-391-5950    Alicia_Kaneb@MEEI.HARVARD.EDU   
Principal Investigator: Racheal Huckfeldt, Dr         
United States, Michigan
Kellogg Eye Center Not yet recruiting
Ann Arbor, Michigan, United States, 48105
Contact: Adrienne Chen    734-232-9167    chenad@med.umich.edu   
Principal Investigator: Thiran Jayasundera         
Sponsors and Collaborators
MeiraGTx UK II Ltd
Investigators
Principal Investigator: Michel Michaelides, Prof UCL/Moorfields

Responsible Party: MeiraGTx UK II Ltd
ClinicalTrials.gov Identifier: NCT03349242     History of Changes
Other Study ID Numbers: MGT011
First Posted: November 21, 2017    Key Record Dates
Last Update Posted: January 31, 2018
Last Verified: January 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Retinitis
Retinitis Pigmentosa
Cone-Rod Dystrophies
Retinal Dystrophies
Retinal Diseases
Eye Diseases
Eye Diseases, Hereditary
Retinal Degeneration
Genetic Diseases, Inborn